Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.
Breast Cancer Res Treat
; 169(3): 523-530, 2018 Jun.
Article
in En
| MEDLINE
| ID: mdl-29442264
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Radioisotopes
/
Zirconium
/
Breast Neoplasms
/
Receptor, ErbB-2
/
Radiopharmaceuticals
/
Trastuzumab
/
Positron Emission Tomography Computed Tomography
Type of study:
Diagnostic_studies
/
Prognostic_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Breast Cancer Res Treat
Year:
2018
Type:
Article
Affiliation country:
United States